These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24331572)

  • 1. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.
    Dorff TB; Wilkins C; Hepgur M; Quinn DI
    Clin Genitourin Cancer; 2014 Apr; 12(2):e55-8. PubMed ID: 24331572
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
    Zustovich F; Fabiani F
    Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.
    George DJ; Nabhan C; DeVries T; Whitmore JB; Gomella LG
    Cancer Immunol Res; 2015 Sep; 3(9):1063-9. PubMed ID: 25943532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T.
    McNamara M; Berry W
    Clin Genitourin Cancer; 2015 Oct; 13(5):e361-4. PubMed ID: 25735199
    [No Abstract]   [Full Text] [Related]  

  • 5. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 6. Dovitinib reduces prostate cancer bone metastases.
    Cancer Discov; 2014 Nov; 4(11):OF3. PubMed ID: 25367965
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
    Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
    Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
    Crawford ED; Petrylak DP; Higano CS; Kibel AS; Kantoff PW; Small EJ; Shore ND; Ferrari A
    Can J Urol; 2015 Dec; 22(6):8048-55. PubMed ID: 26688132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral metastases in prostate cancer: an underestimated and understudied subgroup.
    Bourlon MT; Flaig TW
    Oncology (Williston Park); 2014 Nov; 28(11):980-6. PubMed ID: 25403630
    [No Abstract]   [Full Text] [Related]  

  • 10. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.
    Small EJ; Higano CS; Kantoff PW; Whitmore JB; Frohlich MW; Petrylak DP
    Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):259-64. PubMed ID: 24957547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated:
    Boni G; Monari F
    Tumori; 2019 Jun; 105(3):271. PubMed ID: 30866748
    [No Abstract]   [Full Text] [Related]  

  • 12. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
    Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsatellite Instability May Predict Response to Sipuleucel-T in Patients With Prostate Cancer.
    Zhang KJ; Schneider BP; Albany C
    Clin Genitourin Cancer; 2019 Jun; 17(3):238-239. PubMed ID: 31015016
    [No Abstract]   [Full Text] [Related]  

  • 15. Is it possible that one patient may again experience a response to abiraterone acetate withdrawal during an abiraterone acetate rechallenge?
    Maines F; Veccia A; Caffo O
    Eur Urol; 2014 Jul; 66(1):179-80. PubMed ID: 24685435
    [No Abstract]   [Full Text] [Related]  

  • 16. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
    Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.
    Holko P; Kawalec P
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current role of immunotherapy for the treatment of prostate cancer.
    Porfyris O; Kalomoiris P
    J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.
    Bilen MA; Hess KR; Subudhi SK; Aparicio A; Kim J; Zurita-Saavedra AJ; Araujo JC; Corn PG; Stover J; Lin SH; Logothetis CJ; Tu SM
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):583-589. PubMed ID: 28730293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.